Measurement properties and interpretability of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure.

Background: Patient-reported outcome measures (PROMs) are crucial in assessing the impact of dermatological conditions on people's lives, but the existing dermatology-specific PROMs are not recommended for use, according to COSMIN. We developed the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure in partnership with patients. It has strong evidence of content validity, structural validity, internal consistency, acceptability and feasibility.

Comparative Study on Adaptive Bayesian Optimization for Batch Cooling Crystallization for Slow and Fast Kinetic Regimes.

Crystallization kinetic parameter estimation is important for the classification, design, and scale-up of pharmaceutical manufacturing processes. This study investigates the impact of supersaturation and temperature on the induction time, nucleation rate, and growth rate for the compounds lamivudine (slow kinetics) and aspirin (fast kinetics). Adaptive Bayesian optimization (AdBO) has been used to predict experimental conditions that achieve target crystallization kinetic values for each of these parameters of interest.

Evolving and evaluating the OMERACT fellows program: insights and implications from OMERACT 2023 fellows.

Objective: To describe the evolution of the OMERACT Fellows Program (OM FP) and to evaluate the innovative changes implemented in the 2023 program.

Methods: The OM FP, the first of its kind in global rheumatology, was developed in 2000 to mentor early career researchers in methods and processes for reaching evidence-driven consensus for outcome measures in clinical studies. The OM FP has evolved through continuing iterations of face to face and online feedback.

Exploring the complexities of pain phenotypes: OMERACT 2023 chronic pain working group workshop.

Objective: To educate and discuss pain mechanisms (nociceptive, neuropathic, nociplastic) illuminating its possible impact when measuring different outcomes, which may modify, confound and potentially bias the outcome measures applied across various aspects of Rheumatic Musculoskeletal Diseases (RMDs) clinical trials.

Methods: In the plenary presentations, PM lectured on different pain mechanisms and impact on disease activity assessment. Data from two data sets of RMDs patients, which assessed the prevalence and impact of nociplastic pain were presented and reviewed.